The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety, tolerability, and preliminary efficacy results in patients with advanced gastric/gastroesophageal junction adenocarcinoma from a phase Ib/II study of CLDN18.2 CAR T-cell therapy (CT041).
 
Changsong QI
No Relationships to Disclose
 
Chang Liu
No Relationships to Disclose
 
Jifang Gong
No Relationships to Disclose
 
Jian Li
No Relationships to Disclose
 
Dan Liu
No Relationships to Disclose
 
Sai Ge
No Relationships to Disclose
 
Miao Zhang
No Relationships to Disclose
 
Zhi Peng
No Relationships to Disclose
 
Jun Zhou
No Relationships to Disclose
 
Xiaotian Zhang
No Relationships to Disclose
 
Ji Zheng
Employment - CARsgen Therapeutics
Stock and Other Ownership Interests - CARsgen Therapeutics
Honoraria - CARsgen Therapeutics
Travel, Accommodations, Expenses - CARsgen Therapeutics
 
Jun Xiao
Employment - CARsgen Therapeutics
Stock and Other Ownership Interests - CARsgen Therapeutics
Honoraria - CARsgen Therapeutics
Travel, Accommodations, Expenses - CARsgen Therapeutics
 
Daijing Yuan
Employment - CARsgen Therapeutics
Stock and Other Ownership Interests - CARsgen Therapeutics
Honoraria - CARsgen Therapeutics
Travel, Accommodations, Expenses - CARsgen Therapeutics
 
Yueying Peng
Employment - CARsgen Therapeutics
Stock and Other Ownership Interests - CARsgen Therapeutics
Honoraria - CARsgen Therapeutics
Travel, Accommodations, Expenses - CARsgen Therapeutics
 
Huamao Wang
Employment - CARsgen Therapeutics
Leadership - CARsgen Therapeutics
Stock and Other Ownership Interests - CARsgen Therapeutics
Honoraria - CARsgen Therapeutics
Patents, Royalties, Other Intellectual Property - CARsgen Therapeutics
Travel, Accommodations, Expenses - CARsgen Therapeutics
 
Zonghai Li
Employment - CARsgen Therapeutics
Leadership - CARsgen Therapeutics
Stock and Other Ownership Interests - CARsgen Therapeutics
Honoraria - CARsgen Therapeutics
Patents, Royalties, Other Intellectual Property - CARsgen Therapeutics
Travel, Accommodations, Expenses - CARsgen Therapeutics
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squib; Daiichi Sankyo; Harbour BioMed; Merck; Mingji biopharmaceutical; MSD; Roche
Speakers' Bureau - Hutchison Whampoa; MSD
Research Funding - Baiji Shenzhou (Beijing) Biotechnology (Inst); Beijing Xiantong Biomedical Technology (Inst); Nanjing Yaojieankang Biotechnology (Inst); QiLu Pharmaceutical (Inst); Zaiding Pharmaceutical (Inst)